Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.

GeroscienceJul 23, 2026 (epub)
Clinical ResearchNeurologyGeriatricsOpen access

Arne Søraas, Andreas Engvig, Dag Alnæs et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot safety and feasibility study evaluated the effects of young-donor plasma exchange in 12 cognitively impaired patients with mild cognitive impairment and Alzheimer's disease biomarkers. The study aimed to assess the procedure's safety and feasibility, finding that the adverse events were consistent with known risks of plasma exchange, supporting further investigation in larger trials.

Key findings

  • The study involved replacing 16 to 26 L of patient blood plasma with young donor plasma.
  • Adverse events observed were consistent with known risks of plasma exchange.
  • The procedures were deemed feasible for the patient population studied.

Why it matters

Understanding the safety and feasibility of young-donor plasma exchange could pave the way for innovative treatments aimed at cognitive decline in aging populations, potentially improving patient outcomes in neurodegenerative diseases.

Source

PubMed · PMID 42489967Free full text on PubMed Central

Published in Geroscience. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.